Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 2,277 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $50,526.63. Following the completion of the transaction, the insider directly owned 1,158,219 shares of the company’s stock, valued at $25,700,879.61. This represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Apellis Pharmaceuticals Stock Up 1.0%

Shares of Apellis Pharmaceuticals stock opened at $20.53 on Friday. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company has a market cap of $2.60 billion, a P/E ratio of 66.23 and a beta of 0.31. The stock has a 50-day moving average price of $22.88 and a 200 day moving average price of $23.39. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $31.17.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter in the prior year, the business earned ($0.46) EPS. The company’s revenue for the quarter was up 133.0% compared to the same quarter last year. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Needham & Company LLC dropped their price objective on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday. Wells Fargo & Company began coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They set an “overweight” rating and a $32.00 price target on the stock. Cantor Fitzgerald reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday. HC Wainwright lowered their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Finally, Wolfe Research started coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They issued a “peer perform” rating for the company. Eleven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $33.65.

Apellis Pharmaceuticals News Roundup

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterates a Buy on Apellis, signaling continued conviction in longer‑term commercial execution and pipeline upside — a supportive note for investors focused beyond the near term. Wells Fargo Buy Note
• Positive Sentiment: Stifel Nicolaus initiated/issued a Buy (or reiterated) view, adding another constructive Wall Street voice that could help anchor valuation if execution improves. Stifel Buy Note
• Neutral Sentiment: Analysts remain conflicted on Apellis — some highlight upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued mixed research notes and volatile reactions to company updates. Analysts Conflicted
• Negative Sentiment: Apellis disclosed preliminary Q4 U.S. net product revenue of $190M; commentary pointed to weaker Syfovre sales and mixed Empaveli uptake — the primary near‑term catalyst behind a sharp weekly decline and investor concern about commercial momentum. Zacks Coverage on Revenue/Weak Sales
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) cut forecasts or turned more pessimistic, increasing downward pressure by lowering investor expectations and modelled revenues. Cantor Fitzgerald Note Needham Note
• Negative Sentiment: Significant insider selling: multiple senior execs (CEO, CFO, GC and others) sold shares on Jan. 13 — the volume of insider disposals can be read negatively by the market even though filings show they retain large stakes. SEC Form 4 (CEO Sale)
• Negative Sentiment: Options flow showed a >500% spike in put purchases (6,398 puts), indicating elevated hedging and bearish bets that can amplify short‑term volatility and downside pressure. Source: options flow report

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Corton Capital Inc. bought a new position in shares of Apellis Pharmaceuticals during the 2nd quarter worth about $364,000. Simplify Asset Management Inc. bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at $2,419,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Apellis Pharmaceuticals by 43.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock valued at $1,838,000 after purchasing an additional 30,507 shares in the last quarter. Highland Capital Management LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $1,135,000. Finally, Schroder Investment Management Group grew its holdings in shares of Apellis Pharmaceuticals by 91.9% in the 2nd quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock worth $8,406,000 after purchasing an additional 232,506 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.